Evidence map›Paper›PMID 36100357›Full record

ArticleEvidence-based mental health2022

Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment.

Helena Kyunghee Kim, Daniel M Blumberger, Jordan F Karp, Eric Lenze, Charles F Reynolds, Benoit H Mulsant

Open access · greenAbstract read
In one paragraph

Article in Evidence-based mental health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Article
  3. Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Helena Kyunghee KimDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6578-2109
Daniel M BlumbergerDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Jordan F KarpDepartment of Psychiatry, University of Arizona, Tucson, Arizona, USA.
Eric LenzeDepartment of Psychiatry, University of Washington, St. Louis, Missouri, USA.
Charles F ReynoldsDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Benoit H MulsantDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada benoit.mulsant@utoronto.ca.
Centre for Addiction and Mental Health · CAUniversity of Arizona · USUniversity of Pittsburgh · USUniversity of Toronto · CAUniversity of Washington · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
RESEARCH METHODS COREP30MH090333 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEW, MARY AMANDA · 2011 to 2015
$8.3M
1/3-Incomplete Response in Late-Life Depression: Getting to RemissionR01MH083660 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REYNOLDS, CHARLES F. · 2009 to 2013
$2.7M
2/3-Incomplete Response in Late-Life Depression: Getting to RemissionR01MH083648 · NIMH · WASHINGTON UNIVERSITY · PI LENZE, ERIC J · 2009 to 2013
$2.0M
3/3-Incomplete Response in Late-Life Depression: Getting to RemissionR01MH083643 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MULSANT, BENOIT H · 2009 to 2013
$1.3M
Complex Trials for Severe Geriatric Mood DisordersK24MH069430 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MULSANT, BENOIT H · 2004 to 2008
$601k
NCATS NIH HHS UL1 TR000448NIMH NIH HHS K24 MH069430NIMH NIH HHS P30 MH090333NIMH NIH HHS R01 MH083643NIMH NIH HHS R01 MH083648NIMH NIH HHS R01 MH083660
6 · The paper itself

Abstract

backgroundPredictors of antidepressant response in older patients with major depressive disorder (MDD) need to be confirmed before they can guide treatment.

objectiveTo create decision trees for early identification of older patients with MDD who are unlikely to respond to 12 weeks of antidepressant treatment, we analysed data from 454 older participants treated with venlafaxine XR (150-300 mg/day) for up to 12 weeks in the Incomplete Response in Late-Life Depression: Getting to Remission study.

methodsWe selected the earliest decision point when we could detect participants who had not yet responded (defined as >50% symptom improvement) but would do so after 12 weeks of treatment. Using receiver operating characteristic models, we created two decision trees to minimise either false identification of future responders (false positives) or false identification of future non-responders (false negatives). These decision trees integrated baseline characteristics and treatment response at the early decision point as predictors. FINDING: We selected week 4 as the optimal early decision point. Both decision trees shared minimal symptom reduction at week 4, longer episode duration and not having responded to an antidepressant previously as predictors of non-response. Test negative predictive values of the leftmost terminal node of the two trees were 77.4% and 76.6%, respectively.

conclusionOur decision trees have the potential to guide treatment in older patients with MDD but they require to be validated in other larger samples. CLINICAL IMPLICATIONS: Once confirmed, our findings may be used to guide changes in antidepressant treatment in older patients with poor early response.

Indexed as

Major Depressive DisorderAgedAntidepressive AgentsDecision TreesHumansTreatment OutcomeVenlafaxine HydrochlorideAntidepressive AgentsVenlafaxine HydrochlorideAdult psychiatryDepression & mood disorders

Identifiers

PMID36100357
PMCPMC10134194
OpenAlexW4295759372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.